Kos Biotechnology Partners, a global life sciences investment firm focused on connecting the U.S. biopharma ecosystem with Europe, announced the third closing of its inaugural global life sciences fund, bringing total capital commitments to $123 million (€106 million).
Launched in December 2025, the fund has attracted support from a group of institutional investors and family offices, including lead investor Hellenic Development Bank of Investments. According to the firm, the vehicle represents the first life sciences-focused investment fund established in Greece and is the largest venture capital fund launch in the country’s history. It is also among the largest first-time life sciences venture capital fund launches in Europe.
Kos invests across all stages of company development, from formation through Series C financings. The firm focuses on three primary sectors: biotechnology and novel therapeutics, pharmaceutical services, and technology-enabled healthcare platforms.
The company was founded by Dr. Simos Simeonidis and Alex Tzoukas, who sought to build a bridge between scientific innovation and drug-development expertise in the United States and the growing life sciences ecosystem in Europe. Simeonidis combines medical training from Columbia and Harvard Medical Schools with experience analyzing biotechnology companies at Morgan Stanley, Cowen & Co., and RBC, as well as investment experience at Sarissa Capital and Ally Bridge Group.
Tzoukas brings more than a decade of healthcare investment banking and private equity experience from positions held at Deutsche Bank, MTS Health Partners, and Gurnet Point Capital. Nikos Kostaras serves as the firm’s third partner and previously led operations in Greece for IQVIA.
Kos said its investment strategy spans first-in-class and best-in-class therapeutics targeting unmet medical needs, next-generation pharmaceutical services platforms, and computational technologies that use data infrastructure and machine learning to improve drug development.
The firm is also supported by an advisory network composed of scientists, clinicians, and biopharmaceutical executives from the Greek diaspora in the United States, helping portfolio companies access global expertise and international networks.
Kos has already completed two investments. The firm led a financing round for the tech-enabled pharmaceutical services company Epikast and also made an investment in a San Francisco-based biotechnology company, which has yet to be publicly announced. Additional investments are expected later this year.
The firm operates from offices in New York and Athens and currently manages $123 million in assets.
KEY QUOTES:
“The convergence of novel biology with data science and advanced computing is creating unprecedented opportunities to cure complex diseases. Our mission is to back exceptional entrepreneurs redefining the standard of care by leveraging our proprietary international network to connect US drug development know-how with specialized scientific talent.”
Dr. Simos Simeonidis, Co-Founder And Managing Partner, Kos Biotechnology Partners
“Securing our third closing at $123 million in just a few months validates our cross-border thesis and underscores the immense potential of bridging US scientific innovation and drug development expertise with Europe’s advancing life sciences ecosystem. Our ability to invest flexibly across all growth stages ensures Kos can function as a committed, long-term operational partner to innovators transforming human health.”
Alex Tzoukas, Co-Founder And Managing Partner, Kos Biotechnology Partners